ArticleInternational journal of medical sciences2010
Gain of a 500-fold sensitivity on an intravital MR contrast agent based on an endohedral gadolinium-cluster-fullerene-conjugate: a new chance in cancer diagnostics.
Article in International journal of medical sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Structurally Defined Water-Soluble Metallofullerene Derivatives towards Biomedical Applications.Angewandte Chemie (International ed. in English) · 2023Article
- Functionalized Carbon Nanoparticles as Theranostic Agents and Their Future Clinical Utility in Oncology.Bioengineering (Basel, Switzerland) · 2023Review
- Non-Functionalized Fullerenes and Endofullerenes in Aqueous Dispersions as Superoxide Scavengers.Molecules (Basel, Switzerland) · 2020Article
- The structural, magnetic and optical properties of TMScientific reports · 2017Article
- The key energy scales of Gd-based metallofullerene determined by resonant inelastic x-ray scattering spectroscopy.Scientific reports · 2017Article
- SPPS resins impact the PNA-syntheses' improvement.International journal of medical sciences · 2013Article
- A platform for specific delivery of lanthanide-scandium mixed-metal cluster fullerenes into target cells.ChemistryOpen · 2012Article
- BioShuttle mobility in living cells studied with high-resolution FCS & CLSM methodologies.International journal of medical sciences · 2012Article
- Improved synthesis strategy for peptide nucleic acids (PNA) appropriate for cell-specific fluorescence imaging.International journal of medical sciences · 2012Article
- Enhancement of the click chemistry for the inverse Diels Alder technology by functionalization of amide-based monomers.International journal of medical sciences · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among the applications of fullerene technology in health sciences the expanding field of magnetic resonance imaging (MRI) of molecular processes is most challenging. Here we present the synthesis and application of a Gd(x)Sc(3-x)N@C(80)-BioShuttle-conjugate referred to as Gd-cluster@-BioShuttle, which features high proton relaxation and, in comparison to the commonly used contrast agents, high signal enhancement at very low Gd concentrations. This modularly designed contrast agent represents a new tool for improved monitoring and evaluation of interventions at the gene transcription level. Also, a widespread monitoring to track individual cells is possible, as well as sensing of microenvironments. Furthermore, BioShuttle can also deliver constructs for transfection or active pharmaceutical ingredients, and scaffolding for incorporation with the host's body. Using the Gd-cluster@-BioShuttle as MRI contrast agent allows an improved evaluation of radio- or chemotherapy treated tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.